China Food and Drug Administration

China Food and Drug Administration
Agency name	China Food and Drug Administration
Native name	国家食品药品监督管理总局 (former)
Formed	2013
Preceded by	State Administration for Industry and Commerce; Ministry of Health (PRC); State Food and Drug Administration
Dissolved	2018 (functions reorganized)
Superseding	National Medical Products Administration; State Administration for Market Regulation
Jurisdiction	People's Republic of China
Headquarters	Beijing
Chief1 name	(various)
Parent agency	State Council (PRC)

China Food and Drug Administration was a ministerial-level agency established in 2013 to centralize oversight of pharmaceutical, medical device, cosmetic, and food safety regulation in the People's Republic of China. It consolidated functions previously held by agencies such as the State Food and Drug Administration, Ministry of Health (PRC), General Administration of Quality Supervision, Inspection and Quarantine, and State Administration for Industry and Commerce. The agency operated during a period of heightened public focus on safety scandals involving Sanlu Group, Changsheng Biotechnology, GSK China, and others, before major administrative reforms in 2018 transferred its duties to newly created bodies.

History

The agency's creation in 2013 followed earlier regulatory lineage from the State Food and Drug Administration and reform initiatives dating to the 1990s reforms of the Ministry of Health (PRC), the aftermath of the 2003 SARS outbreak, and high-profile incidents such as the 2008 Chinese milk scandal involving Sanlu Group. Its mandate evolved amid policy debates in the 12th National People's Congress and directives from the State Council (PRC). During its existence the agency responded to international pressures from stakeholders including the World Health Organization, Food and Agriculture Organization, World Trade Organization, and bilateral engagements with regulators like the U.S. Food and Drug Administration, European Medicines Agency, and Pharmaceutical Research and Manufacturers of America. In 2018, a comprehensive restructuring announced by the State Council (PRC) created the National Medical Products Administration and the State Administration for Market Regulation, absorbing many of the agency's functions.

Organization and Structure

The agency's internal architecture mirrored modern administrative models seen in bodies such as the European Commission's Directorate-General for Health and Food Safety and the U.S. Department of Health and Human Services. Its departments included divisions for pharmaceuticals, medical devices, cosmetics, food safety, inspection, supervision, and international cooperation, interfacing with provincial branches like the Beijing Municipal Commission of Health and Family Planning, the Shanghai Municipal Food and Drug Administration, and the Guangdong Food and Drug Administration. Senior leadership engaged with entities such as the National Health Commission (PRC), the Ministry of Commerce (PRC), the Ministry of Industry and Information Technology, and provincial people's congresses. The agency also maintained technical centers and laboratories collaborating with institutions like the Chinese Academy of Sciences, Peking University Health Science Center, Tsinghua University School of Medicine, and the China National Center for Food Safety Risk Assessment.

Functions and Responsibilities

Mandated responsibilities paralleled those of regulators such as the U.S. Food and Drug Administration and the European Medicines Agency, covering registration and approval of pharmaceuticals, licensing of medical device manufacturers, cosmetic product oversight, food safety supervision, post-market surveillance, and adverse event reporting. It administered standards aligned with organisations like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and negotiated regulatory recognition with agencies such as the Pharmaceutical Inspection Co-operation Scheme. The agency managed clinical trial approvals in conjunction with academic hospitals such as Peking Union Medical College Hospital, oversaw good manufacturing practice inspections related to corporations like Sinopharm and Sino Biopharmaceutical, and participated in public health emergency responses alongside the Chinese Center for Disease Control and Prevention and the National Health Commission (PRC).

Regulatory Framework and Policies

The agency implemented laws and regulations derived from statutes like the Drug Administration Law of the People's Republic of China and the Food Safety Law of the People's Republic of China, amending administrative measures for cosmetic registration, medical device supervision, and pharmaceutical advertising in response to cases involving GSK China and Changsheng Biotechnology. It promulgated technical guidelines referencing international standards from the World Health Organization and the International Organization for Standardization, and engaged in bilateral memoranda with authorities such as the European Commission and the U.S. Food and Drug Administration to streamline inspection and approval processes.

Enforcement and Compliance

Enforcement mechanisms included market inspections, product recalls, administrative penalties, criminal referrals to procuratorates in coordination with bodies like the Supreme People's Procuratorate, and public disclosure of enforcement actions. The agency coordinated recall actions affecting firms including Sanlu Group and Changsheng Biotechnology, and worked with customs authorities such as the General Administration of Customs (PRC) on import controls. Compliance programs emphasized good manufacturing practice, pharmacovigilance, and traceability systems similar to initiatives by the European Medicines Agency and U.S. Food and Drug Administration.

Major Reforms and Mergers

Major organizational changes culminated in the 2018 overhaul directed by the State Council (PRC), which created the National Medical Products Administration and consolidated market supervision under the State Administration for Market Regulation. This reform followed earlier shifts prompted by the 2008 Chinese milk scandal, the 2013 drug quality incidents, and legislative revisions at sessions of the National People's Congress. The reorganization intended to reduce fragmentation seen across entities such as the General Administration of Quality Supervision, Inspection and Quarantine and the Ministry of Health (PRC).

Criticisms and Controversies

The agency faced scrutiny over regulatory failures highlighted by scandals involving Sanlu Group, Changsheng Biotechnology, and disputes with multinationals like GSK China over bribery allegations. Critics cited issues in inspection capacity, local government interference prominent in provinces like Hebei and Jiangsu, and challenges in enforcing standards across enterprises including Sinovac and Guangzhou Pharmaceutical Holdings Limited. International observers such as the World Health Organization and foreign governments questioned transparency and post-market surveillance effectiveness, while domestic commentators referenced reform debates within the Chinese Academy of Social Sciences and coverage by media outlets like Xinhua News Agency and China Daily.

Category:Defunct government agencies of China